Sedation is near-universal, and propofol is the drug of choice.
Pun et al. 2021,Lancet Respiratory Medicine
What: across 69 ICUs and 2,088 ventilated patients, 71% received propofol, typically for a week, and the median patient was deeply sedated.
Why it matters: propofol is used at huge scale, and patients still sit in deep sedation despite guidance.Soliman et al. 2001, British Journal of Anaesthesia
What: a survey of 647 intensive care doctors in 16 European countries showed wide national differences in which sedatives were used and how.
Why it matters: sedation practice is driven by habit and local culture, not by measurement.Carrasco et al. 1993, Chest
What: propofol kept patients at the target sedation level more of the time than midazolam, with faster and more predictable recovery.
Why it matters: propofol’s predictability is why it became the standard agent, and why its blood level is meaningful to measure.Andrade et al. 2021, Revista Brasileira de Terapia Intensiva
What: compared with midazolam, propofol shortened ICU stay by about 48 hours and ventilation by about 22 hours, and saved roughly US$3,000 per patient.
Why it matters: propofol has the strongest economic case, so managing it well matters most.
Important Investment Information
This website contains information about Somnus Scientific Limited that is directed exclusively at professional investors.
In the United Kingdom, this information is intended only for investment professionals and high net worth entities within the meaning of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended), or other persons to whom it may lawfully be communicated.
In the United States, any investment-related information is intended solely for persons who qualify as “Accredited Investors” under Regulation D of the Securities Act of 1933.
Nothing on this website constitutes an offer to sell or a solicitation of an offer to buy any securities. Any investment will be made only on the basis of formal investment documentation provided separately.
Investments in early-stage medical technology companies are high risk. Capital is at risk and investors may lose some or all of their investment. Prospective investors should seek independent professional advice before making any investment decision.